Renaud Prudent; Hugues Lemoine; Jarrod Walsh; Didier Roche
Drug Discov. Today, 2023, 103760
https://doi.org/10.1016/j.drudis.2023.103760

Abstract

Affinity selection mass spectrometry (AS-MS) has gained momentum in drug discovery. This review summarizes how this technology has slowly risen as a new paradigm in hit identification and its potential synergy with DNA encoded library technology. It presents an overview of the recent results on challenging targets and perspectives on new areas of research, such as RNA targeting with small molecules. The versatility of the approach is illustrated and strategic drivers discussed in terms of the experience of a small-medium CRO and a big pharma organization.
Teaser: This review highlights the interest aroused by AS-MS as a screening technology, assessing the shared experience of a small-medium contract research organization (CRO) and a big pharma organization.